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ABSTRACT 
Objective: Toxicity profiles of diverse anti-neoplastic drugs are extensively documented in past decades and the protective role of natural products 
against such toxic drugs plays a vital role in the evolution of chemoprevention. Globally, Cyclophosphamide (CYP) is used as an anticancer drug, but 
now it has been limited due to its acute and chronic cardio toxicity. Hence the present study was designed to investigate the protective role of 
Geraniol (GOH) against CYP induced cardio toxicity. 
Methods: The activity of serum marker enzymes and lipoprotein fractions, cardiac marker enzymes and lipid profiles as well as antioxidant status 
was done using standard procedures in vivo. In addition, optimum dosage of GOH was determined as obtained by the levels of serum marker 
enzymes for tissue damage and the pathological changes were assessed by histology. 
Results: Administration of CYP to rats results in hoisted levels of marker enzymes (in both serum and heart tissue) and reduced levels of 
antioxidants. GOH (200 mg/kg body weight) restrained the elevation of marker enzymes (in both serum and heart tissue) and augmented the levels 
of antioxidants. Moreover, histological observations added proofs to the protective role of GOH against cardiac damage.  
Conclusion: CYP administered pathological changes were attenuated by the oral treatment of GOH at a dose of 200 mg/kg body weight of rat and 
suggests that the cardioprotective effects could be related to up regulation of antioxidant mechanism. Conclusive outcome from our findings 
suggests that GOH might be a potential chemo preventive agent in attenuating drug induced cardio toxicity. 
Keywords: Cyclophosphamide, Geraniol, Cardiotoxicity. 
 
INTRODUCTION 
Most of antineoplastic chemotherapeutic agents result in 
cytotoxicity to one or more target tissues [1]. Now a day, most 
research on anticancer dosing strategies focusses on minimizing 
cytotoxicity rather than optimizing efficacy. In addition, most 
antineoplastic cytotoxic agents have diverse action modes [2]. 
Cardio toxicity can be induced by various chemotherapeutic agents, 
in particular by alkylating agents such as cyclophosphamide (CYP). 
Alkylating agents are a class of anticancer drugs that are awfully 
reactive and can bind covalently to a numerous biomolecules. CYP 
(N, N-Bis (2-chloroethyl) tetrahydro-2H-1, 3, 2-oxazaphosphorine-2-
mine-2-oxide) (fig.1b) is an oxazaphosphorine alkylating agent, 
which is often used in chemotherapy and immunosuppressive 
treatment protocols [3]. It is widely used as a remedial platform for 
chronic and acute leukemias, lymphomas, multiple myeloma and 
rheumatic arthritis and also in the preparation for bone marrow 
transplantation [4-5]. The ability of CYP to interfere with normal cell 
division in all proliferating tissues provides the support for its 
therapeutic effects and many of toxic properties [3]. The major 
imperfection of CYP is the damage of normal tissue, end up in 
multiple organ toxicity. The critical factor for both therapeutic and 
toxic effects of CYP is the need of metabolic activation by hepatic 
microsomal cytochrome P450 mixed functional oxidase system [6-
9]. It is already mentioned that high therapeutic doses of CYP could 
cause a noxious cardio toxicity that has an integration of symptoms 
and signs of myopericarditis leading to lethal complications like 
arrhythmias, congestive heart failure, myocardial depression and 
cardiac tamponade. The pathogenesis of CYP-induced acute cardio 
toxicity was ascribed to the elevation in free oxygen radicals and the 
destruction in the antioxidant defense mechanism. Impaired 
secretion of heart lipoprotein lipase, hypertriglyceridemia and 
hypercholesterolemia have been reported in CYP-treated rabbits 
[10-13]. Moreover, it has been reported that CYP induced its acute 
cardio toxicity by hoisting inner mitochondrial membrane 
permeability to calcium and reducing the activities of Krebs cycle 
enzymes with the subsequent uncoupling of mitochondrial-linked 
ATP synthesis [14, 15]. In 1972, cardiotoxicity was first influenced 
by CYP as a complication of bone marrow transplantation [16]. In 
the procedures of bone marrow transplantation and peripheral 
blood stem cell transplantation (PBSCT), high-dose chemotherapy 
including CYP, is enormously used. After one week administration of 
CYP results in acute heart failure secondary to cardio toxicity and 
the incidence rate is about 20% and mortality about 8% after bone 
marrow transplantation [17-18]. In addition, cardio toxicity 
associated with high-dose CYP have been reported as an 
impediment of various therapeutic regimens [19-20]. Therefore, 
there is an indeed requirement for the novel therapeutic agents, 
which helps in the protection of normal tissue from drug induced 
toxicity with the absence of toxic properties. 
 
 
Fig. 1: a) Structure of Geraniol [GOH] and b) Cyclophosphamide 
[CYP] 
 
Essential oils and their constituents have been used widely in 
traditional medicine for their diverse pharmaceutical actions. Recent 
days, plant-derived products to be of great focus due to their 
multiple pharmacological activities [21-25]. Monoterpenes are one 
such plant derivatives which possess diverse medicinal properties 
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and these components are considered as a new class of chemo 
preventive agents. Geraniol (GOH; 3, 7-dimethyl-2, 6-octadien-1-ol) 
(fig.1a), an acyclic monoterpene is predominantly found in citrus 
fruits, lemongrass and aromatic herb oils. GOH is a colorless oily 
liquid soluble only in solvents. It is a primary part of palmarosa oil, 
rose oil and citronella oil [26]. Experimental studies have 
demonstrated numerous biological effects of GOH including 
antibacterial [27], antifungal [28], anti-inflammatory [29], 
antioxidant [30], anti-cancer [30] and anti-ulcer activity [31]. In 
addition, recent studies reveal that GOH have significant 
neuroprotective and hepatoprotective activity [32-33]. But still, 
there is no relevant data available on the cardioprotective effect of 
GOH. Hence this study is designed in such a way to elucidate the 
cardioprotective role of GOH on experimentally induced 
cardiotoxicity. We analyzed the profiles of serum and tissue marker 
enzymes as well as serum and tissue lipids status. In addition, we 
studied the alteration on antioxidant enzymes and histopathological 
evaluation was done to assess the pathological change that occurs in 
rats during tissue damage.  
MATERIALS AND METHODS 
Source of chemicals and drugs 
Cyclophosphamide (Cytoxan®
Experimental animals 
) was purchased from Hi Media 
laboratories, India. GOH was purchased from Sigma-Aldrich, 
Bangalore. All other chemicals used were of analytical grade 
obtained from SRL/TCI/HIMEDIA laboratories, India. 
Male albino Wistar rats weighing about 150–155 g were procured 
from TANUVAS, Chennai, India. The animals were house caged 
under suitable environmental conditions (25±2 °C) and were 
acclimatized to 12-h light: 12-h dark cycles. Animals were fed with 
commercially available standard rat pelleted feed (M/S Hindustan 
Foods Ltd, Bangalore, India) throughout the experimental period. 
The animals had free access to water. All the experiments were 
designed and conducted according to the ethical norms approved by 
Institutional Animal Ethics Committee guidelines (IAEC No. 
17/01/2014). 
Experimental design (fig. 2) 
Group I Normal control rats received corn oil which served as a 
vehicle (0.25 ml/100g body weight) throughout the experimental 
period along with standard diet and drinking water. 
Group II Rats received the standard diet and drinking water throughout 
the experimental period and on the first day of experiment, a single dose 
of CYP (200 mg/kg body weight, intraperitoneally using saline) was 
given [34] and maintained for 10 days. 
Group III Rats were treated with GOH (dissolved in corn oil) alone 
by orally at a dose of 200 mg/kg body weight (based on effective 
dose fixation studies) on all the days of the experimental period (10 
days).  
Note: Various doses of GOH (100, 200, 300, 400 mg/kg body weight) 
were administered orally to the CYP intoxicated animals to optimize 
the GOH dose for its maximum efficacy in the minimum dose, 
determined by the levels of serum marker enzymes for tissue 
damage (data shown in fig. 3). It was found that 200 mg/kg body 
weight of GOH has the maximum protective efficacy in the minimum 
dose.  
Group IV Rats were treated with GOH (200 mg/kg body weight 
dissolved in corn oil 0.25 ml/100g body weight)) to the CYP induced 
group of rats from the day 1 till the end of the experimental period.  
At the end of the experimental period, the animals were 
anesthetized with Ketamine (90 mg/kg) and Xylazine (10 mg/kg) 
and sacrificed by cervical decapitation. Blood was collected and 
allowed to coagulate at room temperature for 30 min. Serum was 
separated by centrifugation at 3000 rpm for 15 min at 4 ˚C. The heart 
was immediately separated and washed in ice-cold saline. The 
tissues were sliced and homogenized in 0.1 M Tris–HCL buffer (pH 
7.4). The homogenates were centrifuged at 1000 rpm for 10 min at 
4˚C in a cooling centrifuge. The supernatants were separated and 
used for analyzing various parameters. 
 
 
Fig. 2: Schematic representation of experimental design carried 
out for this study 
 
 
Fig. 3: Effect of different doses of GOH on control and CYP 
induced experimental groups of rats. Results are expressed as 
mean±SD for six rats in each group 
 
Biochemical parameters 
Estimation of marker enzymes 
Activities of creatinine kinase [35], lactate dehydrogenase (LDH) 
[36], aspartate transaminases (AST) [37], alanine transaminases 
(ALT) [37] and alkaline phosphatase (ALP) [38] were estimated in 
serum and tissue samples.  
Estimation of enzymic and non-enzymic antioxidants 
Enzymatic antioxidant such as superoxide dismutase (SOD) [39], 
catalase (CAT) [40], glutathione peroxidase (Gpx) [41], glutathione 
reductase (GR), glutathione S-transferase (GST) [42] and non-
enzymic antioxidant such as glucose-6-phosphate dehydrogenase 
(G6PD) [43], vitamin C (VIT C) [44], vitamin E (VIT E) [45], vitamin 
A (VIT A) [46]and glutathione (GSH) [47] content were assayed in 
tissue homogenate.  
Estimation of Serum lipoprotein fractions 
Serum lipoproteiens such as LDL, HDL and VLDL [48] were 
estimated in serum samples. 
Estimation of Cardiac lipid status 
Cardiac lipids such as free cholesterol [49], esterified cholesterol 
[49], phospholipids [50-51], free fatty acids [52] and triglycerides 
[53] content were assayed in tissue homogenate. 
Histological evaluation 
Histological evaluation was performed on a portion of the heart 
tissue after fixation with 10% formalin, embedded in paraffin wax, 
sectioned and was stained with hematoxylin and eosin to assess the 
pathological changes. 
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Statistical analysis 
All data obtained were analyzed by Students-t-test using MS-Excel, 
represented as mean±SD. for six animals (n=6) in each group. The 
results were computed statistically (SPSS/10 software package; 
SPSS Inc., Chicago, IL, USA) using one-way ANOVA. Post hoc testing 
was performed for intercomparisons using the LSD. In all tests, the 
level of statistical significance was set at p<0.05. 
RESULTS 
Effect of GOH on body weight, heart weight and relative heart 
weight 
The cardioprotective effect of GOH against CYP induced tissue 
damage was elucidated in male Wistar albino rats. During the 
experimental period, animals were administered with CYP (200 
mg/kg body weight, intraperitoneally using saline) and GOH (200 
mg/kg body weight dissolved in corn oil 0.25 ml/100g body weight) 
and all rats showed greater tolerance to treatment with GOH. There 
were no death records in experimental groups. Fig. 4 shows Initial 
body weight and final body weight of the control and experimental 
group of animals. In CYP administered animals, there is a significant 
(p<0.05) reduction in the final body weight whereas GOH treated 
animals showed significant (p<0.05) gain in the final body weight 
when compared to CYP administered group II rats. In addition, there 
was no significant difference in the body weight of GOH alone 
treated rats compared to control rats. 
 
 
Fig. 4: Effect of GOH on Initial body weight and final body weight 
of control and experimental groups of rats 
Results are expressed as mean±SD for six rats in each group. 
Statistical significance at p<0.05 compared with aCompared with 
control andb
Fig. 5 depicts the heart weight and relative heart weight of control 
and experimental group of animals. CYP induced rats distinctly 
augmented the heart weight and relative heart weight compared to 
group I control animals.  
Compared with CYP administered group. 
The GOH treated group IV animals exhibited obvious decrease in the 
heart weight and relative heart weight when compared with CYP 
administered animals. No distinct difference found between the 
control and GOH alone treated animals which clearly represent the 
nontoxic property of GOH.  
 
 
Fig. 5: Effect of GOH on heart weight and relative heart weight of 
control and experimental groups of rats 
Results are expressed as mean±SD for six rats in each group. 
Statistical significance at p<0.05 compared with aCompared with 
control and b
Moreover, there is no significant difference between the control and 
GOH alone treated animals. This may clearly indicates that GOH 
possess better restoration potential of cardiac tissue. 
Compared with CYP administered group. 
 
Effect of GOH on the levels of serum and cardiac marker 
enzymes  
Table 1 and 2 depicts the effect of GOH on the levels of marker 
enzymes CK, LDH, AST, ALT and ALP in the serum and heart of 
control and experimental group of rats. The levels of marker 
enzymes are significantly (p<0.05) elevated in CYP-induced animals 
when compared with normal control animals. GOH-treated rats 
showed a significantly (p<0.05) curtailed levels of these enzymes 
when compared with CYP-induced animals.  
 
Table 1: Effect of GOH on the activities of marker enzymes in the serum of control and experimental groups of rats 
Groups CK LDH AST ALT ALP 
Control 86.25±7.40 1006±110 72.32±6.55 23.20±2.17 10.63±1.18 
CYP 176.34±16.32 1543±146a 295.2±23.04 a 78.23±6.25a 26.32±3.09a 
GOH 
a 
86.74±9.74 1087±124 72.84±5.88 22.98±3.11 10.78±0.96 
CYP+GOH 110.24±12.27 1323±139b 121.2±20.33b 45.16±5.27b 13.26±1.79b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control andb
 
 
Compared with CYP. Units — CK: µmol of phosphorus/h/mg protein; LDH, AST and ALT: µmol of pyruvate/h/mg protein; ALP: KA U/l. 
Table 2: Effect of GOH on the activities of Cardiac marker enzymes in the tissue of control and experimental groups of rats 
Groups CK LDH AST ALT 
Control 28.7±2.32 10.06±0.99 7.23±0.41 11.50±1.17 
CYP 8.76±1.04 6.48±0.92a 3.96±0.27a 4.62±0.30a 
GOH 
a 
28.5±2.26 10.87±0.96 7.10±0.47 11.68±1.16 
CYP+GOH 19.76±2.30 8.76±1.01b 5.28±0.76b 8.96±0.96b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control and b
 
 
Compared with CYP. Units — CK: µmol of phosphorus liberated/h/mg protein; LDH, AST and ALT: µmol of pyruvate liberated/h/mg protein.  
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Effect of GOH on antioxidant status in heart 
Table 3 and 4 represents the enzymic and non-enzymic antioxidant 
status in the heart of the control and experimental group of animals. 
CYP induced animals exhibited a significant (p<0.05) destruction in 
the activities of enzymic antioxidants such as SOD, CAT, GPx, GR and 
GST when compared with normal control animals, GOH 
supplemented animals showed a significant (p<0.05) elevation in 
the activities of these enzymes when compared with group 2 CYP-
induced animals. In addition, the activities of non-enzymic 
antioxidants such as GSH, G6PD, VIT A, VIT C and VIT E are also 
significantly declined in CYP induced animals when compared with 
control animals. In GOH treated animals, there is a significant 
(p<0.05) raise in the activities of GSH, G6PD, VIT A, VIT C and VIT E 
when compared with CYP induced animals. No adverse effect was 
observed in GOH alone treated animals. This clearly depicts the 
antioxidant potential of GOH due to its protective levels of enzymic 
and non-enzymic antioxidant status. 
 
Table 3: Effect of GOH on the activities of enzymic antioxidants in the Heart of control and experimental groups of rats 
Groups SOD CAT GPx GR GST 
Control 2.17±0.17 75.06±5.39 20.23±1.41 1.36±0.10 1.09±0.12 
CYP 0.99±0.07 35.48±3.92a 13.96±1.27a 0.63±0.05a 0.68±0.06a 
GOH 
a 
2.22±0.16 76.87±4.96 20.10±1.47 1.27±0.08 1.03±0.14 
CYP+GOH 1.88±0.09 67.76±6.23b 17.28±1.76b 1.01±0.11b 0.87±0.07b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control and b
Units: SOD in units/mg protein, CAT in µmol of H
 
Compared with CYP. 
2O2
 
 decomposed/min/mg protein, GPx in µmol of GSH utilized/min/mg protein, GR in µmol of 
NADPH oxidized/min/mg protein and GST in µmole of CDNB-GSH conjugate formed/min/mg protein.  
Table 4: Effect of GOH on the activities of non-enzymic antioxidants in the Heart of control and experimental groups of rats 
Groups GSH G6PD VITAMIN C VITAMIN E VITAMIN A 
Control 5.76±0.57 1.26±0.13 1.20±0.13 1.83±0.25 1.17±0.10 
CYP 3.39±0.37 0.79±0.06a 0.79±0.09a 1.36±0.07a 0.76±0.02a 
GOH 
a 
5.92±0.56 1.27±0.12 1.22±0.11 1.81±0.27 1.16±0.09 
CYP+GOH 4.88±0.59 1.06±0.10b 1.01±0.10b 1.50±0.16b 1.06±0.07b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control and b
Units: GSH glutathione in g/mg protein, G6PD in µmol of NADPH oxidized/min/mg protein, Vit C in mg/g of wet tissue, Vit E in mg/g of wet tissue 
and Vit A in mg/g of wet tissue and GSH in µg/mg protein. 
 
Compared with CYP. 
 
Effect of GOH on serum lipoprotein-cholesterol profile 
Table 5 shows the serum lipoprotein fractions such as LDL, HDL and 
VLDL of control and experimental groups of rats. The level of HDL 
was significantly (p<0.05) reduced in CYP induced group when 
compared with control animals. The levels of VLDL and LDL were 
significantly (p<0.05) increased in CYP induced group when 
compared with control animals. However, significantly decreased 
levels of VLDL and LDL and elevated levels of HDL were observed in 
GOH treated animals when compared to CYP induced animals. 
 
Table 5: Effect of GOH on serum lipoprotein fractions of control and experimental groups of rats 
Groups LDL HDL VLDL 
Control 11.17±0.87 41.26±4.43 29.20±3.13 
CYP 34.99±2.87 27.79±3.06a 46.79±5.39a 
GOH 
a 
10.89±1.16 41.77±5.12 28.97±3.11 
CYP+GOH 20.88±2.29 36.06±3.70b 35.01±4.10b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control and b
 
Effect of GOH on cardiac lipid status 
 
compared with CYP, Units: mg/dL 
Table 6 portrays the cardiac lipid fractions such as free cholesterol, 
esterified cholesterol, phospholipids, free fatty acids and 
triglycerides. CYP administered animals depict significant increase 
in the content of free cholesterol, esterified cholesterol and 
triglycerides and there was a significant reduction in the content of 
phospholipids and free fatty acids. Supplementation of GOH brought 
about a significant (p<0.05) increase in the content phospholipids 
and free fatty acids and a significant (p<0.05) decline in the free 
cholesterol, esterified cholesterol and triglycerides content of heart, 
relative to CYP alone induced animals. 
 
Table 6: Effect of GOH on cardiac lipids of control and experimental groups of rats 
Groups Free cholesterol Esterified cholesterol Phospholipids Free fatty acids Triglycerides 
Control 3.57±0.47 1.46±0.13 15.20±1.33 3.28±0.33 3.36±0.29 
CYP 4.99±0.27 2.79±0.36a 10.79±0.59a 2.49±0.26a 7.79±0.59a 
GOH 
a 
3.59±0.46 1.41±0.12 14.97±1.31 3.27±0.31 3.39±0.41 
CYP+GOH 4.08±0.38 1.94±0.17b 13.01±0.80b 2.91±0.22b 5.01±0.60b b 
Results are expressed as mean±SD for six rats in each group. Statistical significance at p<0.05 compared with aCompared with control and b 
Compared with CYP, Units: mg/dL 
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Effect of GOH on histological features of heart 
The histology of the heart tissue sections, stained with hematoxylin 
and eosin (H&E) was assessed under a light microscope. Control 
animals (fig. 6A) revealed the normal architecture of the heart 
(appearance of enlarged, swollen mitochondria and vacuoles) and 
GOH alone supplemented animals (fig. 6C) also showed the normal 
histological appearance as compared to normal control animals 
indicating the nontoxic nature of GOH. The CYP induced animals (fig. 
6B) showed myocyte swelling and hyalinization at focal, whereas 
Cyclophosphamide-administered and GOH-treated heart (fig. 6D) 
showing almost normal myocytes and the abnormal pathological 
findings are reduced. These restorations may be due to the 
protective effect of GOH against oxidative stress and tissue damage 
induced by CYP. 
 
 
Fig. 6: Photomicrographs (100x) obtained from 6. A. Control group, 
6. B. CYP group, 6. C. GOH alone group and 6. D. CYP+GOH group 
 
DISCUSSION 
Cyclophosphamide (CYP), a commonly used oxazaphosphorine 
alkylating agent, has been extended from neoplastic diseases to 
organ transplantation and diverse disorders and as an 
immunosuppressive agent. The major limitation of CYP is the injury 
of normal tissue, leading to multiple organ toxicity. It is well 
documented that high therapeutic doses of CYP could cause a lethal 
cardiotoxicity that has a combination of symptoms and signs of 
myopericarditis leading to fatal complications such as congestive 
heart failure, arrhythmias, cardiac tamponade and myocardial 
depression. Cellular mechanisms of CYP-induced cardiotoxicity are 
thought to be mediated by an increase in free oxygen radicals and 
the decrease in the antioxidant defense mechanism [54]. This study 
has been initiated to investigate the possible mechanisms whereby 
GOH could prevent the development of CYP-induced cardiotoxicity.  
In this current study, administration of CYP (200 mg/kg body weight 
in single dose) noticeably reduced body weight significantly 
increased heart weight to overall body weight in comparison with 
normal control rats. In the present investigation, serum 
cardiotoxicity enzymatic indices, CK, LDH, AST and ALP which 
occurred as a result of damaged myocytes and these increase in the 
serum levels are the predominant indicators of cardiac damage. It is 
most likely to be the result of toxic effects of CYP, as elevated levels 
of these enzymes in serum are associated with cardiac injury such as 
myocardial infarction, myocarditis and heart failure. CYP induced 
cardiotoxicity may be due to direct myocardial endothelial damage, 
end up in extravasation of blood containing high levels of the drug 
and resulting in the release of CK and LDH from necrotic cells. GOH 
(200 mg/kg body weight) co-treatment brought back these enzymes 
to near routine level by possibly preserving the functional integrity 
of the myocytes, showing its defense action against CYP induced 
cardiotoxicity. These results are consistent with the data presented 
by several authors, who demonstrated a marked elevation of CK, 
LDH, ALT, and AST, 10 days after administration of a single dose of 
CYP (200 mg/kg) [3, 15, 34, 55]. This protective effect of GOH could 
be due to stabilization of cardiac membranes with the consequent 
decrease in the release of cardiac enzymes. Increased activities of 
cardiac enzymes in serum are well-known diagnostic indicators of 
cardiac injury [55].  
Previous studies by Madan et al., showed 200 mg/kg body weight of 
GOH as a maximum protective dose for oral carcinoma [30]. Hence, 
we tried the same in cardiotoxicity conditions by treating various 
doses of GOH (100, 200, 300, 400 mg/kg body weight) were 
administered orally to the CYP intoxicated animals. It was found that 
200 mg/kg body weight of GOH has the maximum protective efficacy 
in the minimum dose as determined by the levels of serum marker 
enzymes for tissue damage (data shown in fig. 3). Hence, we used 
this concentration as the standard concentration for further 
experimental studies.  
Pathological condition that leads to hoisted production and/or 
abortive scavenging of reactive oxygen species (ROS) may play a 
central role in determining tissue injury. Over production of ROS 
during CYP therapy causes membrane injury by initiating lipid 
peroxidation that result in loss of function and integrity of 
myocardial membranes. Cellular mechanism of toxicity is provoked 
by an increase in the free radicals through intracellular 
phosphoramide mustard and acrolein, the primary alkylating 
metabolites of CYP and it plays a vital role in the occurrence of 
cardiac injury. Several studies revealed the protective nature of 
enzymic antioxidants and non-enzymic antioxidants against 
oxidative damage [22, 34, 55-56]. Destruction in the levels of these 
antioxidant enzymes in the myocytes of CYP administered rats 
occurs as, a result of inactivation of these enzymes by ROS. This 
causes further elevation in the levels of ROS which severely decrease 
the activities of antioxidant enzymes. Reduced levels of the 
antioxidants in myocytes make it more exposed to the free radical 
damage. Mythili et al. reported that CYP (200 mg/kg) induced acute 
cardiotoxicity was attributed to the increase in ROS and the decrease 
in the antioxidant defense mechanisms in the heart and that 
antioxidant compounds attenuated CYP-induced cardiotoxicity [15]. 
In line with this text, in the present study, CYP significantly 
decreased the antioxidant mechanisms (table 3), thus leaving the 
heart tissues with no known defense mechanism against ROS. 
Therefore, hearts from CYP-treated rats are more vulnerable to ROS. 
Interestingly, GOH treated rats showed improved activities of 
antioxidants than CYP intoxicated group. This clearly proves the 
antioxidant capacity of GOH due to its free radical encountering 
activity. Moreover, many studies in our laboratory reporting the 
antioxidant potential of various compounds against cardiotoxicity as 
well as hepatotoxicity which includes Ferulic acid [57], Ascorbic acid 
[57], Squalene [56] and Carvacrol [22].  
SOD and CAT are the primary antioxidants involved in the 
inactivation of environmental carcinogens and in the direct 
elimination of toxic free radicals and electrophiles, resulting in the 
amelioration of oxidative damage [22, 56-59]. In accordance with 
the present findings, the significant decrease in the levels of SOD and 
CAT activity was due to exhaustion of the enzymes as a result of 
oxidative stress and increase in LPO caused by CYP. GPx is a well-
known first line of defense against oxidative stress and several 
studies have reported the decreased activities of GPx in various 
toxicity conditions. GST is a group of multifunctional proteins that 
perform functions ranging from catalyzing the detoxification of 
electrophilic compounds to protection against peroxidative damage. 
GR plays a major role in regenerating GSH from GSSG, thus 
maintaining the balance between the redox couple. This enzyme 
requires NADPH for its activity, which is provided by the action of 
G6PD. Besides, the diminished activity of GPx, GST and GR might be 
owing to the decreased availability of the substrate, GSH and 
increase in the levels of peroxides during cardiotoxicity on CYP 
administered rats. Nevertheless, GOH treatment bolster the 
antioxidant defense mechanism as depicted by the increased tissue 
levels of SOD, CAT, GPx, GST and GR antioxidants. Non-enzymic 
antioxidants such as GSH, Vitamin-E, Vitamin-C and Vitamin-A are 
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closely interlinked to each other and play an excellent role in 
protecting the cell from oxidative damage. Glutathione is a 
ubiquitous tripeptide which functions as a free radical scavenger in 
the oxidative stress conditions [58]. Depletion of GSH impairs the 
ability of the cells to protect against the free radicals and results in 
enhanced LPO. Vitamin E is a lipid soluble antioxidant which is 
present in cellular membranes where it plays an important role in 
the suppression of free radical induced LPO [59]. Vitamin C is a free 
radical scavenger and functions as an antioxidant in recycling the 
Vitamin E radical back to Vitamin E. GSH in tissues keeps up the 
cellular levels of vitamin C and vitamin E in active form. These data 
clearly exemplify the reduced activities of the vitamin C and E, as 
pronounced GSH depletion is observed in the CYP administered 
group. GOH supplemented animals significantly increased the levels 
of all the above antioxidants which may be due to ability GOH to 
interact with hydroxyl and superoxide radicals thereby 
subsequently having the property to scavenge them. The alterations 
in lipoprotein transport and metabolism play an essential role in the 
context of changes in plasma lipids. Data from this study revealed 
that CYP significantly increased cholesterol and triglycerides in 
serum. Hypercholesterolemia, hypertriglyceridemia induced by CYP, 
which are well-known risk factors in cardiovascular diseases, has 
been reported previously. Interestingly, GOH supplementation 
completely reversed the CYP-induced increase in cholesterol and 
triglycerides to the control values. Biochemical data were further 
confirmed by histopathological studies of the cardiac tissues. As CYP 
induction (10 days of its administration) caused marked myocardial 
degeneration in the form of myofibrillar loss, inflammatory cell 
infiltration, cytoplasmic vacuole formation, interstitial edema and 
hemorrhage. These histopathological changes have been previously 
reported in CYP-induced cardiotoxicity [15, 34, 55-57, 60]. GOH 
treated animals revealed the normal architecture of the heart and 
showed better cardioprotection as observed by the absence of 
adverse pathological changes in the heart of CYP induced cardiac 
damage. Thus, GOH may reduce oxidative stress through the direct 
antioxidant effect, leading to the prevention of CYP-induced 
cardiotoxicity. 
CONCLUSION 
The present study from our research findings clearly elaborates the 
significant protective effect of GOH on CYP induced cardiotoxic 
properties by enhanced the levels of antioxidants and reduced levels 
of marker enzymes. It is hypothesized that GOH protects the tissues 
by scavenging the toxic metabolite, which is proved by the 
normalization of the biochemical parameters. Hence, GOH may be 
often considered as an effective chemoprevention model for CYP-
induced cardiotoxicity. 
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